Hypermethylation of the putative tumor-suppressor genes DCC, p51/63 and O 6-methylguanine-DNA methyltransferase (MGMT) and loss of their expressions in cell lines of hematological malignancies

Journal of Nippon Medical School

Volumn 72, Issue 5, 2005, Pages 270-277

  Nakayama, Kazutaka ^a   Inokuchi, Koiti ^a   Dan, Kazuo ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Deleted in colorectal cancer; Loss of expression; Methylation; O 6 methylguanine DNA methyltransferase; p51 p63

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P51; PROTEIN P63; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA FLANKING REGION; DNA METHYLATION; GENE EXPRESSION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CELL LINE, TUMOR; DNA METHYLATION; DNA-BINDING PROTEINS; GENE EXPRESSION; GENES, DCC; GENES, TUMOR SUPPRESSOR; HUMANS; LEUKEMIA; METHYLATION; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PHOSPHOPROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEINS;

EID: 27544445663     PISSN: 13454676     EISSN: 13473409     Source Type: Journal    
DOI: 10.1272/jnms.72.270     Document Type: Article

References (39)

1. Kaelin WG: The emerging p53 gene family. J Natl Cancer Inst 1999; 91: 594-598.
2. Diccianni MB, Yu J, Hsiao M, Mukherjee S, Shao LE, Yu AL: Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. Blood 1994; 84: 3105-3112.
3. Marks DI, Kurz BW, Link MP, Ng E, Shuster JJ, Lauer SJ, Brodsky I, Haines DS: High incidence of potential p53 inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis. Blood 1994; 87: 1155-1161.
4. Liu M, Taketani T, Li R, Takita J, Taki T, Yang HW, Kawaguchi H, Ida K, Matsuo Y, Hayashi Y: Loss of p73 gene expression in lymphoid leukemia cell lines is associated with hypermethylation. Leukemia Res 2000; 25: 441-447.
5. Herman JG, Civin CI, Issa JP, Collector MI, Sharkis SJ, Baylin SB: Distinct patterns of inactivation of p 15 INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 1997; 57: 837-841.
6. INK4B. Cancer Res 1996; 56: 722-727.
7. Hussain A, Gutierrez MI, Timson G, Siraj AK, Deambrogi C, Al-Rasheed M, Gaidano G, Magrath I, Bhatia K: Frequent silencing of fragile histidine triad gene (FHIT) in Burkitt's lymphoma is associated with aberrant hypermethylation. Gene Chromosome Canc 2004; 41: 321-329.
8. Merlo A, Herman JG, Mao L, Gabrielson E, Burger PC, Baylin SB, Sidransky D: 5′CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995; 1: 686-692.
9. Baylin SB, Herman JG, Graff JR, Issa JP: Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998; 72: 141-196.
10. Maesawa C, Tamura G, Suzuki Y, Ogasawara S, Sakata K, Kashiwaba M, Satodate R: The sequential accumulation of genetic alterations characteristic of the colorectal adenoma and adenocarcinoma. J Pathol 1995; 176: 249-258.
11. Halm SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE: DPC4, a candidate tumor suppressor gene at human chromosome 18q21. Science 1996; 271: 350-353.
12. Nishizuka S, Tamura G, Terashima M, Satodate R: Loss of heterozygosity during the development and progression of differentiated adenocarcinoma of the stomach. J Pathol 1998; 185: 38-43.
13. Uchino S, Tsuda H, Noguchi M, Yokota J, Terada M, Saito T, Kobayashi M, Sugimura T, Hirohashi S: Frequent loss of heterozygosity at the DCC locus in gastric cancer. Cancer Res 1992; 52: 3099-3102.
14. Faeron ER, Cho KR, Nigro JM, Kern SE, Simons JW, Ruppert JM, Hamilton SR, Preisinger AC, Thomas G, Kinzler KW: Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 1990; 247: 49-56.
15. Osada M, Ohba M, Kawahara C, Ishioka C, Kanamaru R, Katoh I, Ikawa Y, Nimura Y, Nakagawara A, Obinata M, Ikawa S: Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nature Med 1998; 4: 839-843.
16. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotch V, Andrews NC, Caput D, McKeon F: p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2: 305-316.
17. Baylin SB, Herman JG: DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genets 2000; 16: 168-174.
18. Kaghad M, Bonnet H, Yang A, Creeancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F, Caput D: Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997; 90: 809-819.
19. Yamaguchi H, Inokuchi K, Sakuma Y, Dan K: Mutation of the p51/p63 gene is associated with blastic crisis in chronic myelogenous leukemia. Leukemia 2001; 15: 1729-1734.
20. Oue N, Sigeishi H, Kuniyasu H, Yokozaki H, Kuraoka K, Ito R, Yasui W: Promoter hypermethylation of MGMT is associated with protein loss in gastric carcinoma. Int J Cancer 2001; 93: 805-809.
21. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999; 59: 793-797.
22. Herfarth KK, Brent TP, Danam RP, Remack JS, Kodner IJ, Wells SA: A specific CpG methylation pattern of the MGMT promoter region associated with reduced MGMT expression in primary colorectal cancers. Mol Carcinog 1999; 24: 90-98.
23. Pieper RO, Patel S, Ting SA, Futscher BW, Costello JF: Methylation of CpG island transcription factor binding sites is unnecessary for aberrant silencing of the human MGMT gene. J Biol Chem 1996; 271: 13916-13924.
24. Inokuchi K, Hamaguchi H, Taniwaki M, Yamaguchi H, Tanosaki S, Dan K: Establishment of a cell line with AML1-MTG8, TP53, and TP73 abnormalities from acute myelogenous leukemia . Genes Chromosomes & Cancer 2001; 32: 182-187.
25. Yamaguchi H, Inokuchi K, Hanawa H, Tanosaki S, Shinozawa I, Matuoka H, Dan K: Establishment of a near-triploid human B-cell lymphoma cell line with t (14; 18) and a p53 gene point mutation. British J Haematol 1999; 105: 764-767.
26. Ikezoe T, Miyagi T, Kubota T, Taguchi T, Ohtsuki Y, Miyake K, Inokuchi K, Nomura T, Koeffler HP, Miyoshi I: Inactivation of the DCC tumor suppressor gene in a B-cell lymphoma cell line with the alteration of chromosome 18. Am J Hematol 1995; 50: 124-132.
27. Miyake K, Inokuchi K, Dan K, Nomura T: Alterations in the deleted in colorectal carcinoma gene in human primary leukemia. Blood 1993; 82: 927-930.
28. Inokuchi K, Abo J, Takahashi H, Inokuchi S, Dan K, Nomura T: Establishment and characterization of a villous lymphoma cell line from specific B-cell lymphoma. Leukemia Res 1995; 19: 817-822.
29. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR. A novel PCR assay for methylation status of CpG island. Proc Natl Acad Sci USA 1996; 93: 9821-9826.
30. Herman JG, Umar A, Polyak K: Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998; 95: 6870-6875.
31. Inokuchi K, Yamaguchi H, Hanawa H, Tanosaki S, Nakamura K, Tarusawa M, Miyake K, Shimada T, Dan K: Loss of DCC gene expression is of prognostic importance in acute myelogenous leukemia. Clin Cancer Res 2002; 8: 1882-1888.
32. Sato K, Tamura G, Tuchiya T, Usuba O, Kimura W, Motoyama T: Frequent loss of expression without sequence mutations of the DCC gene in primary gastric cancer. Br J Cancer 2001; 85: 199-203.
33. Graff JR, Herman JG, Myohanen S, Baylin SB, Vertino PM: Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation. J Biol Chem 1997; 272: 22322-22329.
34. Leonard CJ, Canman CE, Kastan MB: The role of p53 in cell cycle control and apoptosis: implications for cancer. Important Adv Oncol 1995; 121: 33-42.
35. Canman CE, Kastan MB: Role of p53 in apoptosis. Adv Pharmacol 1997; 41: 429-460.
36. Steele RJ, Thompson AM, Hall PA, Lane DP: The p53 tumor suppressor gene. Br J Surg 1998; 85: 1460-1467.
37. 6-alkylguanine-DNA alkyltransferase regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 1990; 50: 6119-6129.
38. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343: 1350-1354.
39. 6-methylguanine- DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 2000; 60: 2368-2371.